Genetic approaches to the neurobiology of electroconvulsive therapy

Journal of ECT

Volumn 14, Issue 3, 1998, Pages 206-219

  Fochtmann, Laura J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Autoradiography; Caffeine; Electroconvulsive therapy; Electroshock; Mice; Rats; Receptors, Purinergic P1, N methyl D aspartate; Refractory period, neurologic; Variation, genetic

Indexed keywords

CAFFEINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; ELECTRIC SHOCK; ELECTROCONVULSIVE THERAPY; GENETIC VARIABILITY; MALE; MENTAL DISEASE; MOLECULAR GENETICS; MORTALITY; MOUSE; NEUROBIOLOGY; NONHUMAN; RAT; REFRACTORY PERIOD; SEIZURE; SEIZURE THRESHOLD; TONIC CLONIC SEIZURE;

EID: 0031683508     PISSN: 10950680     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124509-199809000-00006     Document Type: Article

References (66)

1. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150:I-26.
2. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151:1-36.
3. American Psychiatric Association Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. Washington, DC: American Psychiatric Association, 1990.
4. Beale MD, Kellner CH, Pritchett JT, Bernstein HJ, Burns CM, Knapp R. Stimulus dose-titration in ECT: a 2-year clinical experience. Convulsive Ther 1994;10:171-6.
5. Browning RA, Nelson DK. Variation in threshold and pattern of electroshock-induced seizures in rats depending on site of stimulation. Life Sci 1985;37:2205-11.
6. Burley ES, Ferrendelli JA. Regulatory effects of neurotransmitters on electroshock and pentylenetetrazol seizures. Fed Proc 1984;43:2521-4.
7. Calev A, Fink M, Petrides G, Francis A, Fochtmann L. Caffeine pre-treatment enhances clinical efficacy and reduces cognitive effects of ECT. Convulsive Ther 1993;9:95-100.
8. Carney JM, Scale TW, Logan L, McMaster SB. Sensitivity of inbred mice to methylxanthines is not determined by plasma xanthine concentration. Neurosci Lett 1985;56:27-31.
9. Chapouthier G, Bondoux D, Martin B, Desforges C, Launay JM. Genetic difference in sensitivity to beta-carboline: evidence for the involvement of brain benzodiazepine receptors. Brain Res 1991;553:342-6.
10. Coffey CE, Lucke J, Weiner RD, Krystal AD, Aque M. Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold. Biol Psychiatry 1995;37:713-20.
11. Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. Biol Psychiatry 1987;22:637-49.
12. Colenda CC, McCall WV A statistical model predicting the seizure threshold for right unilateral ECT in 106 patients. Convulsive Ther 1996;12:3-12.
13. Craig CG, White TD. N-Methyl-D-aspartate- and non-N-methyl-D-aspartate-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem 1993;60:1073-80.
14. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997;132:107-24
15. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Hormones Behav 1997;31:197-211.
16. Crnic LS. Transgenic and null mutant animals for psychosomatic research. Psychosomat Med 1996;58:622-32.
17. Deckard BS, Lieff B, Schlesinger K, DeFries JC. Developmental patterns of seizure susceptibility in inbred strains of mice. Dev Psychobiol 1976;9:17-24.
18. Dichter MA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia 1994;(suppl 7):35.
19. Engstrom FL, Woodbury DM. Seizure susceptibility in DBA and C57 mice: the effects of various convulsants. Epilepsia 1988;29:389-95.
20. Essig CF, Flanary HG. The importance of the convulsion in occurrence and rate of development of electroconvulsive threshold elevation. Exp Neurol 1966;14:448-52.
21. Fochtmann LJ. Animal studies of electroconvulsive therapy: foundations for future research. Psychopharmacol Bull 1994;30:321-44.
22. Fochtmann LJ, Cruciani R, Aiso M, Potter WZ. Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra. Eur J Pharmacol 1989;167:305-6.
23. Francis A, Dowell F, Kline L, Fochtmann L. Anticonvulsant properties of subconvulsive stimuli in mouse ECS model. Convulsive Ther 1997;13:54.
24. Francis A, Fochtmann L. Caffeine augmentation of electroconvulsive seizures. Psychopharmacology 1994;115:320-4.
25. Francis A, Fochtmann L. Reduced proconvulsant activity of caffeine in rats after a series of electroconvulsive seizures. Psychopharmacology 1995;119:99-104.
26. Francis A, Fochtmann L. Genetic variation in immediate and delayed postictal refractory period in rats. Brain Res 1996;721:150-4.
27. Fredholm BB. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101.
28. Fuller JL, Sjursen FH Jr. Audiogenic seizures in eleven mouse strains. J Hered 1967;58:135-40.
29. Gale K. Subcortical structures and pathways involved in convulsive seizure generation. J Clin Neurophysiol 1992;9:264-77.
30. 125I]Iodo-MK-801 to the NMDA receptor-channel complex in rat brain. Int J Rad Appl Instrum B 1992;19:319-26.
31. 2 receptors, adenylate cyclase, and the adenosine uptake site. J Neurochem 1989;52:641-6.
32. Hinkle PE, Coffey CE, Weiner RD, Cress M, Christison C. Use of caffeine to lengthen seizures in ECT. Am J Psychiatry 1987;144:1143-8.
33. Jarvis MF, Williams M. Differences in adenosine A-1 and A-2 receptor density revealed by autoradiography in methylxanthine-sensitive and insensitive mice. Pharmacol Biochem Behav 1988;30:707-14.
34. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology 1992;6:145-53.
35. Kosobud AE, Crabbe JC. Genetic correlations among inbred strain sensitivities to convulsions induced by 9 convulsant drugs. Brain Res 1990;526:8-16.
36. Kosobud AE, Cross SJ, Crabbe JC. Neural sensitivity to pentylenetetrazol convulsions in inbred and selectively bred mice. Brain Res 1992;592:122-8.
37. Krystal AD, Weiner RD. ECT seizure therapeutic adequacy. Convulsive Ther 1994;10:153-64.
38. Lalla FR, Milroy T. The current status of seizure duration in the practice of electroconvulsive therapy. Can J Psychiatry 1996;41:299-304.
39. Lisanby SH, Devanand DP, Nobler MS, Prudic J, Mullen L, Sackeim HA. Exceptionally high seizure threshold: ECT device limitations. Convulsive Ther 1996;12:156-64.
40. Manzoni OJ, Manabe T, Nicoll RA. Release of adenosine by activation of NMDA receptors in the hippocampus. Science 1994;265:2098-101.
41. McCall WV, Shelp FE, Weiner RD, Austin S, Norris J. Convulsive threshold differences in right unilateral and bilateral ECT. Biol Psychiatry 1993;34:606-11.
42. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44:S1-23.
43. Modrow HE, Holloway FA, Chnstensen HD, Carney JM. Relationship between caffeine discrimination and caffeine plasma levels. Pharmacol Biochem Behav 1981;15:323-5.
44. Newman M, Zohar J, Kalian M, Belmaker RH. The effects of chronic lithium and ECT on A1 and A2 adenosine receptor systems in rat brain. Brain Res 1984;291:188-92.
45. Nobler MS, Sackeim HA, Solomou M, Luber B, Devanand DP, Prudic J. EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry 1993;34:321-30.
46. Parkinson FE, Fredholm BB. Magnesium-dependent enhancement of endogenous agonist binding to A1 adenosine receptors: a complicating factor in quantitative autoradiography. J Neurochem 1992;58:941-50.
47. Paterson AH. Molecular dissection of quantitative traits: progress and prospects. Genome Res 1995;5:321-33.
48. Pazzagli M, Corsi C. Latini S, Pedata F, Pepeu G. In vivo regulation of extracellular adenosine levels in the cerebral cortex by NMDA and muscarinic receptors Eur J Pharmacol 1994;254:277-82.
49. Pollack M, Rosenthal F, Macey R. Changes in electroshock convulsive response with repeated seizures. Exp Neurol 1963;7:98-106.
50. Rasmussen KG, Zorumski CF, Jarvis MR. Possible impact of stimulus duration on seizure threshold in ECT. Convulsive Ther 1994;10:177-80.
51. Sackeim H, Decina P, Prohovnik I, Malitz S. Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry 1987;44:355-60.
52. Sackeim HA, Devanand DP, Prudic J, Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatr Clin North Am 1991;14:803-43.
53. Sagratella S. NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Pharmacol Res 1995;32:1-13.
54. Samoriski GM, Piekut DT, Applegate CD. Differential spatial patterns of fos induction following generalized clonic and generalized tonic seizures. Exp Neurol 1997;143:255-68.
55. Schork NJ, Nath SP, Lindpaintner K, Jacob HJ. Extensions to quantitative trait locus mapping in experimental organisms. Hypertension 1996;28:1104-11.
56. Shapira B, Lerer B, Gilboa D, Drexler H, Kugelmass S, Calev A. Facilitation of ECT by caffeine pretreatment. Am J Psychiatry 1987;144:1199-202.
57. Shapira B, Lidsky D, Gorfine M, Lerer B. Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. J Clin Psychiatry 1996;57:32-8.
58. Stahle L, Segersvard S, Ungerstedt U. Drug distribution studies with microdialysis, II. Caffeine and theophylline in blood, brain and other tissues in rats. Life Sci 1991;49:1843-52.
59. Swartz CM. Repeated ECT stimuli and the seizure threshold. Convulsive Ther 1990;6:181-2.
60. Swartz CM, Larson G. ECT stimulus duration and its efficacy. Ann Clin Psychiatry 1989;1:147-52.
61. Tedeshi DH, Swinyard EA, Goodman LS. Effects of variations in stimulus intensity on maximal electroshock seizure pattern, recovery time and anticonvulsant potency of phenobarbital in mice. J Pharmacol Exp Ther 1956;116:107-13.
62. Toman JEP, Swinyard EA, Goodman LS. Properties of maximal seizures, and their alteration by anticonvulsant drugs and other agents. J Neurophysiol 1946;9:231-9.
63. Torchiana ML, Stone CA. Post-seizure mortality following electroshock convulsions in certain strains of mice. Proc Soc Exp Biol Med 1959;100:290-3.
64. van der Neut R. Targeted gene disruption: applications in neurobiology. J Neurosci Methods 1997;71:19-27.
65. Young D, Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms, Neuroscience 1994;58:245-61.
66. Zhang G, Franklin PH, Murray TF. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 1993;264:1415-24.